A specialty-chemicals turnaround priced like distress as EUR 7.3bn cartel-damages claims turn Clariant into litigation arbitrage.
Overview
Clariant is a structurally complex, high-risk equity story split between improving fundamentals and rapidly worsening legal tail risk. Operationally, the company’s specialty-focused strategy under CEO Conrad Keijzer is working: despite weak global industrial production and strong CHF headwinds, Q3 2025 EBITDA margin before exceptionals rose to 17.9% (+230 bps YoY), supported by pricing power, mix improvement, Lucas Meyer synergy capture, and a CHF 80m efficiency program. Management reiterates credible 2027 targets of 19–21% margins and 4–6% local-currency growth. However, since Oct 2025, Clariant has faced escalating civil damages claims linked to the 2020 EU ethylene purchasing cartel settlement, with disclosed claims exceeding ~EUR 7.3bn—multiple times its ~CHF 2.36bn market cap. The stock has sold off to distressed levels, making 2026 primarily a courtroom-driven, event-risk investment rather than a typical chemicals cycle call.